Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
BIVICTRIX LIMITED currently faces 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These matters are split between 2 distinct examiners and 2 distinct art units. This arrangement shows that the company is managing separate prosecution tracks, each with its own examiner and art unit environment. The use of 2 distinct art units within the Biotechnology & Pharmaceuticals area indicates that the company's intellectual property covers different specialized niches that are examined independently by the patent office.
The busiest examiner for the portfolio is SANG, HONG, who is responsible for 1 pending office action. Given that there are 2 pending office actions in total, the busiest examiner pending count of 1 confirms that no single examiner is handling the entire active workload. Practitioners must prepare for different sets of examiner preferences across the 2 distinct art units currently engaged. This diversification across 2 distinct examiners means that the applicant can compare the progress of the pending office actions to identify which examiner or art unit presents a more favorable path to allowance. However, with only 1 pending office action per examiner, each individual interaction remains critical to the overall success of the portfolio.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SANG, HONG | 1 | 55.0% | +62.4% |
| MERTZ, PREMA MARIA | 1 | 71.7% | +35.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18215953 | ANTI-CD33 AND ANTI-CD7 COMBINATION TREATMENT | SANG, HONG | 19d |
| 18265781 | BISPECIFIC ANTIBODIES BINDING TO CD7 AND CD33 | MERTZ, PREMA MARIA | 34d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18215953 | ANTI-CD33 AND ANTI-CD7 COMBINATION TREATMENT | SANG, HONG | 19d |
| 18265781 | BISPECIFIC ANTIBODIES BINDING TO CD7 AND CD33 | MERTZ, PREMA MARIA | 34d |
| Art Unit | Apps |
|---|---|
| 1646 | 1 |
| 1674 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18215953 | ANTI-CD33 AND ANTI-CD7 COMBINATION TREATMENT | SANG, HONG | 1646 | §103§112Other | Non-Final OA | 19d | Pending | Jun 29, 2023 |
| 18265781 | BISPECIFIC ANTIBODIES BINDING TO CD7 AND CD33 | MERTZ, PREMA MARIA | 1674 | §102§112Other | Non-Final OA | 34d | Pending | Jun 07, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial